TY - JOUR
T1 - Acute graft-versus-host disease
T2 - Pathophysiology, clinical manifestations, and management
AU - Couriel, Daniel
AU - Caldera, Humberto
AU - Champlin, Richard
AU - Komanduri, Krishna
PY - 2004/11/1
Y1 - 2004/11/1
N2 - Hematopoietic stem cell transplantation has evolved as a central treatment modality in the management of different hematologic malignancies. Despite adequate posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in the hematopoietic stem cell transplantation setting, even in patients who receive human leukemic antigen (HLA) identical sibling grafts. Up to 30% of the recipients of stem cells or bone marrow transplantation from HLA-identical related donors and most patients who receive cells from other sources (matched-unrelated, non-HLA-identical siblings, cord blood) will develop > Grade 2 acute GVHD despite immunosuppressive prophylaxis. Thus, GVHD continues to be a major limitation to successful hematopoietic stem cell transplantation. In this review, the authors summarize the most current knowledge on the pathophysiology, clinical manifestations, and management of this potentially life-threatening transplantation complication.
AB - Hematopoietic stem cell transplantation has evolved as a central treatment modality in the management of different hematologic malignancies. Despite adequate posttransplantation immunosuppressive therapy, acute graft-versus-host disease (GVHD) remains a major cause of morbidity and mortality in the hematopoietic stem cell transplantation setting, even in patients who receive human leukemic antigen (HLA) identical sibling grafts. Up to 30% of the recipients of stem cells or bone marrow transplantation from HLA-identical related donors and most patients who receive cells from other sources (matched-unrelated, non-HLA-identical siblings, cord blood) will develop > Grade 2 acute GVHD despite immunosuppressive prophylaxis. Thus, GVHD continues to be a major limitation to successful hematopoietic stem cell transplantation. In this review, the authors summarize the most current knowledge on the pathophysiology, clinical manifestations, and management of this potentially life-threatening transplantation complication.
KW - Hematopoietic stem cell transplantation
KW - Immunosuppressive therapy
KW - Inflammatory cytokines
KW - T-cell subsets
UR - http://www.scopus.com/inward/record.url?scp=7044222314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7044222314&partnerID=8YFLogxK
U2 - 10.1002/cncr.20613
DO - 10.1002/cncr.20613
M3 - Review article
C2 - 15372473
AN - SCOPUS:7044222314
SN - 0008-543X
VL - 101
SP - 1936
EP - 1946
JO - Cancer
JF - Cancer
IS - 9
ER -